Hopp til innhold
NHI.no
Annonse

Spiserørskreft: Prognose

Innhold i artikkelen

Kreft i spiserøret er en alvorlig sykdom med en dårlig prognose. De som blir syke, vil som oftest bli dårligere etter som tiden går. Dessverre oppdages sykdommen som regel på et tidspunkt der sykdommen er langt fremskredet. Det beste man kan gjøre i disse tilfellene, er å gi pasienten lindrende behandling. Ca. 25 prosent er i live 5 år etter at diagnosen ble stilt.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Spiserørskreft . Referanselisten for dette dokumentet vises nedenfor

  1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av spiserørskreft. Helsedirektoratet sist oppdatert 07.02.2020. www.helsebiblioteket.no
  2. Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam Physician. 2017 Jan 1;95(1):22-28. PubMed
  3. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020, www.kreftregisteret.no.
  4. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009;3(2 suppl 1):S2-S5. www.ncbi.nlm.nih.gov
  5. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103(11):2694–2699.
  6. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375–1383.
  7. Xie FJ, Zhang YP, Zheng QQ et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19(36): 6098-107. pmid:24106412 PubMed
  8. Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician 2006; 73: 2187-94. PubMed
  9. Loomis d, Guyton KZ, Grosse Y, et al. Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet oncology 2016. pmid: 27318851 PubMed
  10. Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology. 2011;22(3):344–349.
  11. Kamangar F, Chow WH, Abnet CC, et al. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38:27-57. PubMed
  12. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–617.
  13. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010;32(10):1222–1227.
  14. Corley DA, Kerlikowske K, Verma R, Buffler B. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56. PubMed
  15. Xie FJ, Zhang YP, Zheng QQ, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19(36):6098–6107.
  16. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009;3(2 suppl):S2-S5. pmid: 19461918 PubMed
  17. Stapley S, Peters TJ, Neal RD et al. The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case-control study using electronic records. Br J Cancer. 2013;108:25-31. PMID: 23257895. PubMed
  18. Bartley AN, Washington MK, Colasacco C et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017; 35(4): 446-64. pmid:28129524 PubMed
  19. Krasna MJ. Oesophageal cancer. BMJ Best Practice, last updated Jan 27, 2015.
  20. Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-92. pmid:21684205 PubMed
  21. Choi NC, Gibson MK. Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus. UpToDate, last updated Sep 5, 2012. UpToDate
  22. Johnson E, Gjerlaug BE, Holck-Steen A, et al. Kirurgi og stenting for cancer oesophagi. Tidsskr Nor Lægeforen 2005; 125: 286-8. pmid: 15702148 PubMed
  23. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57(9):1200–1206.
  24. Kaneko K, Ito H, Konishi K et al. Implentation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamos cell carcinomas. Hepatogastroenterology 2002; 49: 699-705. PubMed
  25. Tangen M, Andresen SJ, Moum B, Hauge T. Palliasjon med stent ved kreft i oesophagus og cardia. Tidsskr Nor Lægeforen 2006; 126: 1607-9. PubMed
Annonse
Annonse